All In Biotech

Drug Trial Radar · NCT05140863

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week, Phase 3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Postherpetic Neuralgia

Last checked: Nov 20, 2026Latest source record: Feb 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 372 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

372

Actual

Start

Nov 1, 2021

Primary completion

Dec 22, 2022

Study completion Jan 5, 2023

Sponsor

Sponsor type
Industry
First posted
Dec 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigate the Efficacy and Safety of HSK16149 capsules in Chinese Postherpetic Neuralgia Following 12 Weeks Treatment in Comparison to Placebo

Conditions

  • Postherpetic Neuralgia

Interventions

  • HSK16149 20mg BIDDrug

    HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose

  • HSK16149 40mg BIDDrug

    HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose

  • Placebo BIDDrug

    Placebo, orally twice a day, treatment period; 12-weeks fixed dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the change from baseline in ADPS between HSK16149 and placebo at week 12Time frame: Baseline and week 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital of Chinese Academy of Medical Sciences

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital Of Nanchang University

    Nanchang, Jiangxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.